Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: Update on findings from the initial four rounds of screening in a randomized trial

BJU International

Volumn 102, Issue 11, 2008, Pages 1524-1530

  Grubb III, Robert L ^a   Pinsky, Paul F ^b   Greenlee, Robert T ^g   Izmirlian, Grant ^b   Miller, Anthony B ⁿ   Hickey, Thomas P ^p   Riley, Thomas L ^p   Mabie, Jerome E ^p   Levin, David L ^b   Chia, David ^e   Kramer, Barnett S ^f   Reding, Douglas J ^g   Church, Timothy R ^h   Yokochi, Lance A ⁱ   Kvale, Paul A ^j   Weissfeld, Joel L ^k   Urban, Donald A ^m   Buys, Saundra S ^l   Gelmann, Edward P ^d   Ragard, Lawrence R ^o   Crawford, E David ^c   Prorok, Philip C ^a   Gohagan, John K ^b   Berg, Christine D ^b   Andriole, Gerald L ^a   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g MARSHFIELD CLINIC   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

ⁱ PACIFIC HEALTH RESEARCH INSTITUTE   (United States)

^j HENRY FORD HEALTH SYSTEM   (United States)

^k UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^l UNIVERSITY OF UTAH   (United States)

^m UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF TORONTO   (Canada)

^o WESTAT   (United States)

^p INFORMATION MANAGEMENT SERVICES INC   (United States)

more..

Author keywords

DRE; Prostate cancer; PSA; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; EVALUATION; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; DIGITAL RECTAL EXAMINATION; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PATIENT COMPLIANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 56649091399     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08214.x     Document Type: Article

References (19)

1. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. J Am Med Assoc 1995 273 : 289 94
2. Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. J Am Med Assoc 1996 276 : 1309 15
3. Bartsch G, Horninger W, Klocker H et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol. Austria Urol 2001 58 : 417 24
4. Efstathiou JA, Chen MH, Catalona WJ et al. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology 2006 68 : 342 7
5. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2004. CA Cancer J Clin 2004 54 : 41 52
6. American Urological Association. Prostate-specific antigen (PSA) best practice policy. Oncology (Williston Park) 2000 14 : 77 8
7. Mohler J, Bahnson RR, Boston B et al. National Comprehensive Cancer Network. Practice Guidelines in Oncology, Prostate Cancer. 2007. Available at http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf
8. US Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008 143 : 185 91
9. American College of Physicians. Screening for prostate cancer. Ann Intern Med 1997 126 : 480 4
10. Labrie F, Candas B, Dupont A et al. Screening decreases prostate cancer death. first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999 38 : 83 91
11. Gohagan JK, Prorok PC, Kramer BS, Cornett JE. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. J Urol 1994 152 : 1905 9
12. Prorok PC, Andriole GL, Bresalier RS et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000 21 : 273S 309S
13. Schroder FH, Kranse R, Rietbergen J, Hoedemaeke R, Kirkels W. The European Randomized Study of Screening for Prostate Cancer (ERSPC): an update. Members of the ERSPC, Section Rotterdam. Eur Urol 1999 35 : 539 43
14. Auvinen A, Rietbergen JB, Denis LJ, Schroder FH, Prorok PC. Prospective evaluation plan for randomised trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group. J Med Screen 1996 3 : 97 104
15. Andriole GL, Levin DL, Crawford ED et al. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 2005 97 : 433 8
16. American Joint Committee on Cancer, American Cancer Society and American College of Surgeons. AJCC Cancer Staging Manual, 5th edn. Philadelphia : Lippincott-Raven, 1997
17. Postma R, Schroder FH, van Leenders G et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) - Section Rotterdam a comparison of two rounds of screening. Eur Urol 2007 52 : 89 97
18. Makinen T, Tammela T, Stenman U et al. Second round results of the Finnish population-based prostate cancer screening trial. Clin Can Res 2004 10 : 2231 6
19. Hugosson J, Aus G, Lilja H, Lodding P, Pihl C. Results of a randomized, population -based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004 100 : 1397 405